1. Home
  2. ACIU vs WLAC Comparison

ACIU vs WLAC Comparison

Compare ACIU & WLAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACIU
  • WLAC
  • Stock Information
  • Founded
  • ACIU 2003
  • WLAC 2024
  • Country
  • ACIU Switzerland
  • WLAC United States
  • Employees
  • ACIU N/A
  • WLAC N/A
  • Industry
  • ACIU Biotechnology: Pharmaceutical Preparations
  • WLAC
  • Sector
  • ACIU Health Care
  • WLAC
  • Exchange
  • ACIU Nasdaq
  • WLAC Nasdaq
  • Market Cap
  • ACIU 189.1M
  • WLAC 172.6M
  • IPO Year
  • ACIU 2016
  • WLAC 2024
  • Fundamental
  • Price
  • ACIU $2.02
  • WLAC $10.23
  • Analyst Decision
  • ACIU Strong Buy
  • WLAC
  • Analyst Count
  • ACIU 1
  • WLAC 0
  • Target Price
  • ACIU $12.00
  • WLAC N/A
  • AVG Volume (30 Days)
  • ACIU 128.8K
  • WLAC 51.6K
  • Earning Date
  • ACIU 08-05-2025
  • WLAC 01-01-0001
  • Dividend Yield
  • ACIU N/A
  • WLAC N/A
  • EPS Growth
  • ACIU N/A
  • WLAC N/A
  • EPS
  • ACIU N/A
  • WLAC N/A
  • Revenue
  • ACIU $32,014,254.00
  • WLAC N/A
  • Revenue This Year
  • ACIU N/A
  • WLAC N/A
  • Revenue Next Year
  • ACIU $533.21
  • WLAC N/A
  • P/E Ratio
  • ACIU N/A
  • WLAC $753.14
  • Revenue Growth
  • ACIU 91.20
  • WLAC N/A
  • 52 Week Low
  • ACIU $1.43
  • WLAC $9.80
  • 52 Week High
  • ACIU $4.26
  • WLAC $10.60
  • Technical
  • Relative Strength Index (RSI)
  • ACIU 57.93
  • WLAC N/A
  • Support Level
  • ACIU $2.01
  • WLAC N/A
  • Resistance Level
  • ACIU $2.19
  • WLAC N/A
  • Average True Range (ATR)
  • ACIU 0.14
  • WLAC 0.00
  • MACD
  • ACIU 0.00
  • WLAC 0.00
  • Stochastic Oscillator
  • ACIU 60.75
  • WLAC 0.00

About ACIU AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

About WLAC Willow Lane Acquisition Corp. Class A Ordinary Shares

Willow Lane Acquisition Corp is a blank check company.

Share on Social Networks: